Furthermore, in contrast to cancers like non-small cell lung cancer, where therapeutic strategies have advanced in addressing resistance to PD-1 and PD-L1 inhibitors, although ICB shows some efficacy in EC, its overall response rate remains relatively low and resistance is still a significant issue (100, 101). Here, PDCD1 is linked to non-small cell lung carcinoma.